said its drug to fight the flu, RWJ-270201, will be further delayed, until 2002 at the earliest.
BioCryst has been hard at work on an oral flu inhibitor, essentially a pill that you can take to make the flu go away, but that work will have to wait for Phase III trials on the drug.
, a unit of
Johnson & Johnson
, will be conducting the trials of RWJ-270201 in the northern hemisphere during the upcoming winter.
Shares of BioCryst were recently down $8.06, or 54%, to $7.